|
1
|
Siegel R, Ward E, Brawley O and Jemal A:
Cancer statistics, 2011: The impact of eliminating socioeconomic
and racial disparities on premature cancer deaths. CA Cancer J
Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fruscio R, Corso S, Ceppi L, Garavaglia D,
Garbi A, Floriani I, Franchi D, Cantù MG, Bonazzi CM, Milani R, et
al: Conservative management of early-stage epithelial ovarian
cancer: Results of a large retrospective series. Ann Oncol.
24:138–144. 2013. View Article : Google Scholar
|
|
3
|
Alouini S: Management of ovarian cancer
has changed. Gynecol Oncol. 126:313author reply 314. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pinho SS and Reis CA: Glycosylation in
cancer: Mechanisms and clinical implications. Nat Rev Cancer.
15:540–555. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stowell SR, Ju T and Cummings RD: Protein
glycosylation in cancer. Annu Rev Pathol. 10:473–510. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Abbott KL: Glycomic analysis of ovarian
cancer: Past, present, and future. Cancer Biomark. 8:273–280. 2011.
View Article : Google Scholar
|
|
7
|
Sheta R and Bachvarov D: Role of aberrant
glycosylation in ovarian cancer dissemination. Biomedecial Rev.
25:83–92. 2014. View Article : Google Scholar
|
|
8
|
Tabak LA: The role of mucin-type O-glycans
in eukaryotic development. Semin Cell Dev Biol. 21:616–621. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ten Hagen KG, Fritz TA and Tabak LA: All
in the family: the UDP-GalNAc:polypeptide
N-acetylgalactosaminyltransferases. Glycobiology. 13:1R–16R. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hang HC and Bertozzi CR: The chemistry and
biology of mucin-type O-linked glycosylation. Bioorg Med Chem.
13:5021–5034. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bennett EP, Mandel U, Clausen H, Gerken
TA, Fritz TA and Tabak LA: Control of mucin-type O-glycosylation: A
classification of the polypeptide GalNAc-transferase gene family.
Glycobiology. 22:736–756. 2012. View Article : Google Scholar :
|
|
12
|
Bennett EP, Hassan H, Mandel U,
Mirgorodskaya E, Roepstorff P, Burchell J, Taylor-Papadimitriou J,
Hollingsworth MA, Merkx G, van Kessel AG, et al: Cloning of a human
UDP-N-acetyl-alpha-D-Galactosamine:polypeptide
N-acetylgalactosaminyltransferase that complements other
GalNAc-transferases in complete O-glycosylation of the MUC1 tandem
repeat. J Biol Chem. 273:30472–30481. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Beaman EM and Brooks SA: The extended
ppGalNAc-T family and their functional involvement in the
metastatic cascade. Histol Histopathol. 29:293–304. 2014.
|
|
14
|
Brooks SA, Carter TM, Bennett EP, Clausen
H and Mandel U: Immunolocalisation of members of the polypeptide
N-acetylgalactosaminyl transferase (ppGalNAc-T) family is
consistent with biologically relevant altered cell surface
glycosylation in breast cancer. Acta Histochem. 109:273–284. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang ZQ, Bachvarova M, Morin C, Plante M,
Gregoire J, Renaud MC, Sebastianelli A and Bachvarov D: Role of the
polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer
progression: Possible implications in abnormal mucin
O-glycosylation. Oncotarget. 5:544–560. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sheta R, Woo CM, Roux-Dalvai F, Fournier
F, Bourassa S, Droit A, Bertozzi CR and Bachvarov D: A metabolic
labeling approach for glycoproteomic analysis reveals altered
glycoprotein expression upon GALNT3 knockdown in ovarian cancer
cells. J Proteomics. 145:91–102. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sheta R, Roux-Dalvai F, Woo CM, Fournier
F, Bourassa S, Bertozzi CR, Droit A and Bachvarov D: Proteomic
dataset for altered glycoprotein expression upon GALNT3 knockdown
in ovarian cancer cells. Data Brief. 8:342–349. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Taylor PT and Haverstick D: Re: New
guidelines to evaluate the response to treatment in solid tumors
(ovarian cancer). J Natl Cancer Inst. 97:151author reply 152. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Elgaaen BV, Olstad OK, Sandvik L, Odegaard
E, Sauer T, Staff AC and Gautvik KM: ZNF385B and VEGFA are strongly
differentially expressed in serous ovarian carcinomas and correlate
with survival. PLoS One. 7:e463172012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Marth JD: Complexity in O-linked
oligosaccharide biosynthesis engendered by multiple polypeptide
N-acetylgalactosaminyltransferases. Glycobiology. 6:701–705. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dube DH and Bertozzi CR: Glycans in cancer
and inflammation-potential for therapeutics and diagnostics. Nat
Rev Drug Discov. 4:477–488. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hakomori S: Glycosylation defining cancer
malignancy: New wine in an old bottle. Proc Natl Acad Sci USA.
99:10231–10233. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Christiansen MN, Chik J, Lee L, Anugraham
M, Abrahams JL and Packer NH: Cell surface protein glycosylation in
cancer. Proteomics. 14:525–546. 2014. View Article : Google Scholar
|
|
24
|
Fuster MM and Esko JD: The sweet and sour
of cancer: Glycans as novel therapeutic targets. Nat Rev Cancer.
5:526–542. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang R, Yu C, Zhao D, Wu M and Yang Z: The
mucin-type glycosylating enzyme polypeptide
N-acetylgalactosaminyltransferase 14 promotes the migration of
ovarian cancer by modifying mucin 13. Oncol Rep. 30:667–676. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lin MC, Huang MJ, Liu CH, Yang TL and
Huang MC: GALNT2 enhances migration and invasion of oral squamous
cell carcinoma by regulating EGFR glycosylation and activity. Oral
Oncol. 50:478–484. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ho WL, Chou CH, Jeng YM, Lu MY, Yang YL,
Jou ST, Lin DT, Chang HH, Lin KH, Hsu WM, et al: GALNT2 suppresses
malignant phenotypes through IGF-1 receptor and predicts favorable
prognosis in neuroblastoma. Oncotarget. 5:12247–12259. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu YM, Liu CH, Hu RH, Huang MJ, Lee JJ,
Chen CH, Huang J, Lai HS, Lee PH, Hsu WM, et al: Mucin
glycosylating enzyme GALNT2 regulates the malignant character of
hepatocellular carcinoma by modifying the EGF receptor. Cancer Res.
71:7270–7279. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu SY, Shun CT, Hung KY, Juan HF, Hsu CL,
Huang MC and Lai IR: Mucin glycosylating enzyme GALNT2 suppresses
malignancy in gastric adenocarcinoma by reducing MET
phos-phorylation. Oncotarget. 7:11251–11262. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wright PK, May FE, Darby S, Saif R,
Lennard TW and Westley BR: Estrogen regulates vesicle trafficking
gene expression in EFF-3, EFM-19 and MCF-7 breast cancer cells. Int
J Clin Exp Pathol. 2:463–475. 2009.PubMed/NCBI
|
|
31
|
Niang B, Jin L, Chen X, Guo X, Zhang H, Wu
Q, Padhiar AA, Xiao M, Fang D and Zhang J: GalNAc-T4 putatively
modulates the estrogen regulatory network through FOXA1
glycosylation in human breast cancer cells. Mol Cell Biochem.
411:393–402. 2016. View Article : Google Scholar
|
|
32
|
Zhang J, Zhang Z, Wang Q, Xing XJ and Zhao
Y: Overexpression of microRNA-365 inhibits breast cancer cell
growth and chemoresistance through GALNT4. Eur Rev Med Pharmacol
Sci. 20:4710–4718. 2016.PubMed/NCBI
|
|
33
|
Liu Y, Liu W, Xu L, Liu H, Zhang W, Zhu Y,
Xu J and Gu J: GALNT4 predicts clinical outcome in patients with
clear cell renal cell carcinoma. J Urol. 192:1534–1541. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li Z, Yamada S, Wu Y, Wang KY, Liu YP,
Uramoto H, Kohno K and Sasaguri Y: Polypeptide
N-acetylgalactosaminyltransferase-6 expression independently
predicts poor overall survival in patients with lung adenocarcinoma
after curative resection. Oncotarget. 7:54463–54473. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Freire-de-Lima L, Gelfenbeyn K, Ding Y,
Mandel U, Clausen H, Handa K and Hakomori SI: Involvement of
O-glycosylation defining oncofetal fibronectin in
epithelial-mesenchymal transition process. Proc Natl Acad Sci USA.
108:17690–17695. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tarhan YE, Kato T, Jang M, Haga Y, Ueda K,
Nakamura Y and Park JH: Morphological changes, cadherin switching,
and growth suppression in pancreatic cancer by GALNT6 knockdown.
Neoplasia. 18:265–272. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gomes J, Marcos NT, Berois N, Osinaga E,
Magalhães A, Pinto-de-Sousa J, Almeida R, Gärtner F and Reis CA:
Expression of UDP-N-acetyl-D-galactosamine: Polypeptide
N-acetylgalactosaminyltransferase-6 in gastric mucosa, intestinal
metaplasia, and gastric carcinoma. J Histochem Cytochem. 57:79–86.
2009. View Article : Google Scholar :
|
|
38
|
Liesche F, Kölbl AC, Ilmer M, Hutter S,
Jeschke U and Andergassen U: Role of
N-acetylgalactosaminyltransferase 6 in early tumorigenesis and
formation of metastasis. Mol Med Rep. 13:4309–4314. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Park JH, Nishidate T, Kijima K, Ohashi T,
Takegawa K, Fujikane T, Hirata K, Nakamura Y and Katagiri T:
Critical roles of mucin 1 glycosylation by transactivated
polypeptide N-acetylgalactosaminyltransferase 6 in mammary
carcinogenesis. Cancer Res. 70:2759–2769. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Park JH, Katagiri T, Chung S, Kijima K and
Nakamura Y: Polypeptide N-acetylgalactosaminyltransferase 6
disrupts mammary acinar morphogenesis through O-glycosylation of
fibronectin. Neoplasia. 13:320–326. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Berois N, Mazal D, Ubillos L, Trajtenberg
F, Nicolas A, Sastre-Garau X, Magdelenat H and Osinaga E:
UDP-N-acetyl-D-galactosamine: Polypeptide
N-acetylgalactosaminyltransferase-6 as a new immunohistochemical
breast cancer marker. J Histochem Cytochem. 54:317–328. 2006.
View Article : Google Scholar
|
|
42
|
Freire T, Berois N, Sóñora C, Varangot M,
Barrios E and Osinaga E: UDP-N-acetyl-D-galactosamine:polypeptide
N-acetylgalactosaminyltransferase 6 (ppGalNAc-T6) mRNA as a
potential new marker for detection of bone marrow-disseminated
breast cancer cells. Int J Cancer. 119:1383–1388. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Patani N, Jiang W and Mokbel K: Prognostic
utility of glycosyltransferase expression in breast cancer. Cancer
Genomics Proteomics. 5:333–340. 2008.
|
|
44
|
Kölbl AC, Hiller RA, Ilmer M, Liesche F,
Heublein S, Schröder L, Hutter S, Friese K, Jeschke U and
Andergassen U: Glycosyltransferases as marker genes for the
quantitative polymerase chain reaction-based detection of
circulating tumour cells from blood samples of patients with breast
cancer undergoing adjuvant therapy. Mol Med Rep. 12:2933–2938.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Pangeni RP, Channathodiyil P, Huen DS,
Eagles LW, Johal BK, Pasha D, Hadjistephanou N, Nevell O, Davies
CL, Adewumi AI, et al: The GALNT9, BNC1 and CCDC8 genes are
frequently epigenetically dysregulated in breast tumours that
metastasise to the brain. Clin Epigenetics. 7:572015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Berois N, Gattolliat CH, Barrios E,
Capandeguy L, Douc-Rasy S, Valteau-Couanet D, Bénard J and Osinaga
E: GALNT9 gene expression is a prognostic marker in neuroblastoma
patients. Clin Chem. 59:225–233. 2013. View Article : Google Scholar
|
|
47
|
Tuupanen S, Hänninen UA, Kondelin J, von
Nandelstadh P, Cajuso T, Gylfe AE, Katainen R, Tanskanen T,
Ristolainen H, Böhm J, et al: Identification of 33 candidate
oncogenes by screening for base-specific mutations. Br J Cancer.
111:1657–1662. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Keita M, Wang ZQ, Pelletier JF, Bachvarova
M, Plante M, Gregoire J, Renaud MC, Mes-Masson AM, Paquet ÉR and
Bachvarov D: Global methylation profiling in serous ovarian cancer
is indicative for distinct aberrant DNA methylation signatures
associated with tumor aggressiveness and disease progression.
Gynecol Oncol. 128:356–363. 2013. View Article : Google Scholar
|
|
49
|
Huanna T, Tao Z, Xiangfei W, Longfei A,
Yuanyuan X, Jianhua W, Cuifang Z, Manjing J, Wenjing C, Shaochuan
Q, et al: GALNT14 mediates tumor invasion and migration in breast
cancer cell MCF-7. Mol Carcinog. 54:1159–1171. 2015. View Article : Google Scholar
|
|
50
|
Wu C, Guo X, Wang W, Wang Y, Shan Y, Zhang
B, Song W, Ma S, Ge J, Deng H, et al:
N-Acetylgalactosaminyltransferase-14 as a potential biomarker for
breast cancer by immunohistochemistry. BMC Cancer. 10:1232010.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kwon OS, Oh E, Park JR, Lee JS, Bae GY,
Koo JH, Kim H, Choi YL, Choi YS, Kim J, et al: GalNAc-T14 promotes
metastasis through Wnt dependent HOXB9 expression in lung
adenocarcinoma. Oncotarget. 6:41916–41928. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wagner KW, Punnoose EA, Januario T,
Lawrence DA, Pitti RM, Lancaster K, Lee D, von Goetz M, Yee SF,
Totpal K, et al: Death-receptor O-glycosylation controls tumor-cell
sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med.
13:1070–1077. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wu C, Shan Y, Liu X, Song W, Wang J, Zou
M, Wang M and Xu D: GalNAc-T14 may be involved in regulating the
apoptotic action of IGFBP-3. J Biosci. 34:389–395. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Liang KH, Lin CL, Chen SF, Chiu CW, Yang
PC, Chang ML, Lin CC, Sung KF, Yeh C, Hung CF, et al: GALNT14
genotype effectively predicts the therapeutic response in
unresectable hepatocellular carcinoma treated with transcatheter
arterial chemoembolization. Pharmacogenomics. 17:353–366. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Lin WR, Chiang JM, Liang KH, Lim SN, Lai
MW, Tsou YK, Hsieh TY, Hsu CK and Yeh CT: GALNT14 genotype predicts
postoperative outcome of stage III colorectal cancer with
oxaliplatin as adjuvant chemotherapy. Medicine (Baltimore).
95:e34872016. View Article : Google Scholar
|
|
56
|
Liang KH, Lin CC and Yeh CT: GALNT14 SNP
as a potential predictor of response to combination chemotherapy
using 5-FU, mitoxantrone and cisplatin in advanced HCC.
Pharmacogenomics. 12:1061–1073. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Soria JC, Márk Z, Zatloukal P, Szima B,
Albert I, Juhász E, Pujol JL, Kozielski J, Baker N, Smethurst D, et
al: Randomized phase II study of dulanermin in combination with
paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell
lung cancer. J Clin Oncol. 29:4442–4451. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Thorburn A, Behbakht K and Ford H: TRAIL
receptor-targeted therapeutics: Resistance mechanisms and
strategies to avoid them. Drug Resist Updat. 11:17–24. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Bennett EP, Hassan H, Mandel U,
Hollingsworth MA, Akisawa N, Ikematsu Y, Merkx G, van Kessel AG,
Olofsson S and Clausen H: Cloning and characterization of a close
homologue of human UDP-N-acetyl-alpha-D-galactosamine:Polypeptide
N-acetylgalactosaminyltransferase-T3, designated GalNAc-T6.
Evidence for genetic but not functional redundancy. J Biol Chem.
274:25362–25370. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Li Z, Yamada S, Inenaga S, Imamura T, Wu
Y, Wang KY, Shimajiri S, Nakano R, Izumi H, Kohno K, et al:
Polypeptide N-acetylgalactosaminyltransferase 6 expression in
pancreatic cancer is an independent prognostic factor indicating
better overall survival. Br J Cancer. 104:1882–1889. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kitada S, Yamada S, Kuma A, Ouchi S,
Tasaki T, Nabeshima A, Noguchi H, Wang KY, Shimajiri S, Nakano R,
et al: Polypeptide N-acetylgalactosaminyl transferase 3
independently predicts high-grade tumours and poor prognosis in
patients with renal cell carcinomas. Br J Cancer. 109:472–481.
2013. View Article : Google Scholar : PubMed/NCBI
|
